{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:10:42Z","timestamp":1791277842073,"version":"4.1.0"},"reference-count":76,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban), and the direct thrombin inhibitor dabigatran. Especially the oral direct FXa and FIIa inhibitors overcome many of the shortcomings of heparins and vitamin K antagonists (VKAs). They are administered orally at a fixed dose; regular monitoring is not necessary; interaction with other drugs or nutrition occur less than with VKAs and they are at least as effective as VKAs for most indications tested. They are associated with about 50 % less intracranial bleeding than VKAs. Nevertheless, they are still associated with bleeding complications. Bleeding can occur spontaneously or as a result of trauma or urgent surgery. In such situations rapid reversal of the anticoagulant effect is highly desirable. For unfractionated heparin protamine, and for VKAs prothrombin complex concentrates are available as specific antidotes. Under clinical development are: for the direct and indirect FXa inhibitors a modified recombinant FXa (andexanet alpha), which lacks enzymatic activity; and for dabigatran a Fab fragment of a monoclonal antibody (idarucizumab). In addition a small molecule (aripazine) has entered phase I clinical trials, which seems to inhibit nearly all anticoagulants but VKAs and argatroban. This review summarises the current options and strategies in development to antagonise anticoagulants with a focus on the status of the development of antidotes for the oral direct FXa and FIIa inhibitors.<\/jats:p>","DOI":"10.1160\/th14-11-0982","type":"journal-article","created":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T10:51:27Z","timestamp":1427971887000},"page":"931-942","source":"Crossref","is-referenced-by-count":123,"title":["Reversal of anticoagulants: an overview of current developments"],"prefix":"10.1160","volume":"113","author":[{"given":"Thomas","family":"Thiele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Selleng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"10.1160\/TH14-11-0982-1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1103053"},{"key":"10.1160\/TH14-11-0982-2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"10.1160\/TH14-11-0982-3","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.4.707"},{"key":"10.1160\/TH14-11-0982-4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615"},{"key":"10.1160\/TH14-11-0982-5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10.1160\/TH14-11-0982-6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-571232"},{"key":"10.1160\/TH14-11-0982-7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/s-0038-1653794","volume":"73","author":"Wolzt","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH14-11-0982-8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.20.2469"},{"key":"10.1160\/TH14-11-0982-9","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1160\/TH14-11-0982-10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02904.x"},{"key":"10.1160\/TH14-11-0982-11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0037-1615374","volume":"80","author":"Kohler","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH14-11-0982-12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"10.1160\/TH14-11-0982-13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04793.x"},{"key":"10.1160\/TH14-11-0982-14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078696"},{"key":"10.1160\/TH14-11-0982-15","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-03-0179"},{"key":"10.1160\/TH14-11-0982-16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577"},{"key":"10.1160\/TH14-11-0982-17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht134"},{"key":"10.1160\/TH14-11-0982-18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01570213"},{"key":"10.1160\/TH14-11-0982-19","unstructured":"Selleng K, Thiele T, S\u00fcmnig A, et al. Dabigatran may redistribute into the vascular compartment after hemodialysis - a case report. H\u00e4mostaseologie 2013; 33: A60 (abstract)"},{"key":"10.1160\/TH14-11-0982-20","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-06-0547"},{"key":"10.1160\/TH14-11-0982-21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3102"},{"key":"10.1160\/TH14-11-0982-22","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12601"},{"key":"10.1160\/TH14-11-0982-23","doi-asserted-by":"crossref","unstructured":"Hollenbach S, Lu G, DeGuzman F, et al. Andexanet-alfa and PER977 (Arapazine) Correct Blood Loss in a Rabbit Liver Laceration Model - Only Andexanet Reverses Markers of fXa-mediated Anticoagulation Circulation 2014; 130: A14657 (abstract)","DOI":"10.1161\/circ.130.suppl_2.14657"},{"issue":"5 Suppl.","key":"10.1160\/TH14-11-0982-24","first-page":"abstract","volume":"33","author":"Crowther","year":"2013","journal-title":"Arterioscl Thromb Vasc Biol"},{"issue":"Suppl","key":"10.1160\/TH14-11-0982-25","first-page":"abstract","volume":"11","author":"Crowther","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1160\/TH14-11-0982-26","doi-asserted-by":"crossref","unstructured":"Crowther MA, Mathur V, Kitt M, et al. A phase 2 randomized, double blind placebo controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alpha (PRT064445), an antidote for factor Xa inhibitors. 2013; 55th ASH annual meeting, New Orleans (abstract): https:\/\/ashconfexcom\/ash\/2013\/webprogram\/Paper56863html","DOI":"10.1182\/blood.V124.21.4269.4269"},{"key":"10.1160\/TH14-11-0982-27","unstructured":"Crowther MA, Lu G, Conley P, et al. Sustained reversal of apixaban anticoagulation with andexanet alpha using a bolus plus infusion regimen in a phase II placebo controlled trial. Eur Heart J 2014; 35 (Suppl.): 137 (abstract)"},{"key":"10.1160\/TH14-11-0982-28","doi-asserted-by":"crossref","unstructured":"Crowther MA, Levy G, Lu G, et al. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. ASH 2014, 6-9.12. 2014; Abstract 4269","DOI":"10.1182\/blood.V124.21.4269.4269"},{"key":"10.1160\/TH14-11-0982-29","doi-asserted-by":"crossref","unstructured":"Crowther M, Levy G, Lu G, et al. ANNEXA\u2122-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. AHA presentation Nov 2014. 2014; Session CS.03. (abstract)","DOI":"10.1182\/blood.V124.21.4269.4269"},{"key":"10.1160\/TH14-11-0982-30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040528"},{"key":"10.1160\/TH14-11-0982-31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3241"},{"key":"10.1160\/TH14-11-0982-32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468207"},{"key":"10.1160\/TH14-11-0982-33","doi-asserted-by":"crossref","unstructured":"Arellano-Rodrigo E, Lopez-Vilchez E, Molina P, et al. Idarucizumab Fully Restores Dabigatran-Induced Alterations on Platelet and Fibrin Deposition on Damaged Vessels: Studies in Vitro with Circulating Human Blood. ASH 2014, 6-912. 2014; Abstract 2878","DOI":"10.1182\/blood.V124.21.2878.2878"},{"key":"10.1160\/TH14-11-0982-34","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-08-0712"},{"key":"10.1160\/TH14-11-0982-35","doi-asserted-by":"crossref","unstructured":"Grottke O, Honickel M, van Ryn J, et al. A specific antidote to dabigatran reduces blood loss in dabigatran- and trauma-induced bleeding in pigs. J Am Coll Cardiol 2014; 63 (abstract)","DOI":"10.1016\/S0735-1097(14)60295-3"},{"key":"10.1160\/TH14-11-0982-36","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-12-1080"},{"key":"10.1160\/TH14-11-0982-37","doi-asserted-by":"crossref","unstructured":"Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete, and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Presentation at AHA, Dallas, TX, USA 2013; Abstract","DOI":"10.1182\/blood.V124.21.344.344"},{"key":"10.1160\/TH14-11-0982-38","doi-asserted-by":"crossref","unstructured":"Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. ASH 2014, 6-9.12.2014; Abstract 344","DOI":"10.1182\/blood.V124.21.344.344"},{"key":"10.1160\/TH14-11-0982-39","doi-asserted-by":"crossref","unstructured":"van Ryn J, Schmoll M, Pillu H, et al. Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss Circulation 2014; 130: A18403 (abstract)","DOI":"10.1161\/circ.130.suppl_2.18403"},{"key":"10.1160\/TH14-11-0982-40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra066469"},{"key":"10.1160\/TH14-11-0982-41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01829.x"},{"key":"10.1160\/TH14-11-0982-42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2054"},{"key":"10.1160\/TH14-11-0982-43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00159"},{"key":"10.1160\/TH14-11-0982-44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.3.830"},{"key":"10.1160\/TH14-11-0982-45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7385"},{"key":"10.1160\/TH14-11-0982-46","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-10-39"},{"key":"10.1160\/TH14-11-0982-47","doi-asserted-by":"crossref","unstructured":"Loeffler DA, Klaver AC, Coffey MP. Abeta anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration. Autoimmunity 2014; 1-5","DOI":"10.3109\/08916934.2014.983265"},{"key":"10.1160\/TH14-11-0982-48","first-page":"Abstract","volume":"126","author":"Laulicht","year":"2012","journal-title":"Circulation"},{"key":"10.1160\/TH14-11-0982-49","unstructured":"Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. presented at the 24th Congress of the International Socienty on Thrombosis and Hemostasis, Amsterdam 2013; Abstract"},{"key":"10.1160\/TH14-11-0982-50","doi-asserted-by":"crossref","unstructured":"Lu G, Kotha J, Cardenas JM, et al. In Vitro Characterisation of Andexanet Alfa (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent Circulation 2014; 130: A18218 (abstract)","DOI":"10.1161\/circ.130.suppl_2.18218"},{"key":"10.1160\/TH14-11-0982-51","doi-asserted-by":"crossref","unstructured":"Bakhru SH, Laulicht B, Jiang X, et al. Reversal of Anticoagulant-induced Bleeding in External and Internal Bleeding Models by PER977, a Small Molecule Anticoagulant Antidote. Circulation 2014; 130: A19361 (abstract)","DOI":"10.1161\/circ.130.suppl_2.19361"},{"key":"10.1160\/TH14-11-0982-52","doi-asserted-by":"crossref","unstructured":"Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. N Engl J Med 2014; Epub ahead of print","DOI":"10.1056\/NEJMc1411800"},{"key":"10.1160\/TH14-11-0982-53","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.022"},{"key":"10.1160\/TH14-11-0982-54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025313"},{"key":"10.1160\/TH14-11-0982-55","doi-asserted-by":"publisher","DOI":"10.5482\/ha-1151"},{"key":"10.1160\/TH14-11-0982-56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"10.1160\/TH14-11-0982-57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207541"},{"key":"10.1160\/TH14-11-0982-58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"10.1160\/TH14-11-0982-59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007432"},{"key":"10.1160\/TH14-11-0982-60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"10.1160\/TH14-11-0982-61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"10.1160\/TH14-11-0982-62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH14-11-0982-63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"10.1160\/TH14-11-0982-64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"10.1160\/TH14-11-0982-65","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht039"},{"key":"10.1160\/TH14-11-0982-66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"10.1160\/TH14-11-0982-67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004450"},{"key":"10.1160\/TH14-11-0982-68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113697"},{"key":"10.1160\/TH14-11-0982-69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"10.1160\/TH14-11-0982-70","first-page":"CD009893","volume":"3","author":"Salazar","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1160\/TH14-11-0982-71","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu181"},{"key":"10.1160\/TH14-11-0982-72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-423228"},{"key":"10.1160\/TH14-11-0982-73","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.825605"},{"key":"10.1160\/TH14-11-0982-74","doi-asserted-by":"crossref","unstructured":"Chong BH, Magnani H. Danaparoid for the treatment of heparin-induced thrombocytopenie. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; 2013. pp. 478-501","DOI":"10.3109\/9781841848617-19"},{"key":"10.1160\/TH14-11-0982-75","doi-asserted-by":"crossref","unstructured":"Rice L, Beiderlinden M, Hursting MJ. Argatroban therapy in heparin-induce thrombocytopenia. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; 2013. pp. 368-399","DOI":"10.3109\/9781841848617-16"},{"key":"10.1160\/TH14-11-0982-76","unstructured":"Warkentin TE, Eikelboom J. Fondaparinux and other emerging anticoagulants to treat heparin induced thrombocytopenia. In: Heparin-induced thrombocytopenia. 5th ed. Boca Raton: Taylor and Francis Group; 2013. pp. 502-532"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH14-11-0982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T23:26:21Z","timestamp":1651620381000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH14-11-0982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":76,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2017,11,24]]},"published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1160\/th14-11-0982","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725418418.793526313","asserted-by":"object"}]},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}